John Hancock and MIT AgeLab’s second index finds no change since 2025, with care the weakest area and community the strongest ...

Steven Austad and Arlan Richardson explore animal longevity, fasting, GLP-1s and biomarkers to reveal what could translate to ...

Prenuvo and UT Dallas researchers found links between sleep efficiency, visceral fat and brain volume, with long sleepers ...

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...

Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.

Arrowhead says its RNAi drug crossed the blood-brain barrier in healthy volunteers and sharply lowered tau, a protein tied to Alzheimer’s.

Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.

The Boston company says the deal more than doubles its patient reach and opens a path to brain-based sleep testing in primary care from 2027.

NeuroXT’s NEXT-Cue pairs brain MRI with cognitive scores to help clinicians assess patients with mild cognitive impairment. Picture the follow-up appointment after a diagnosis of mild cognitive ...

United Therapeutics will test treprostinil SMI in about 40 patients with pulmonary hypertension linked to COPD.

XellSmart’s off-the-shelf XS411 lifted motor scores in nine patients, and its 30-person Phase II trial has finished enrolling ...

As pharma shops for de-risked science, venture money is moving later and concentrating in fewer, bigger bets – our report ...